ASCO 2019: Kantar debates results from the KEYNOTE-062 trial

There were a number of noteworthy outcomes from the KEYNOTE-062 trial that was presented on day two of ASCO 2019 in Chicago.
02 June 2019
cancer cells
Get in touch

The study looked at Merck & Co’s Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority.

Kantar’s Debbie Warner and Michael Gaschler debate the results in the video below.

Get in touch


Over 1500 scientific and peer-reviewed articles to further understanding in health research.
Search the database